Equities

Argent Biopharma Ltd

Argent Biopharma Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.32
  • Today's Change0.00 / 0.00%
  • Shares traded21.71k
  • 1 Year change-84.00%
  • Beta1.3288
Data delayed at least 20 minutes, as of Sep 20 2024 07:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in AUDIncome statement in AUDView more

Income statement information is not available for Argent Biopharma Ltd.
Gross margin21.87%
Net profit margin-1,295.20%
Operating margin-1,175.76%
Return on assets-105.32%
Return on equity--
Return on investment-345.98%
More ▼

Cash flow in AUDView more

In 2024, Argent Biopharma Ltd increased its cash reserves by 193.08%, or 463.05k. Cash Flow from Financing totalled 14.87m or 1,668.25% of revenues. In addition the company used 14.26m for operations while cash used for investing totalled 140.12k.
Cash flow per share-1.21
Price/Cash flow per share--
Book value per share0.0372
Tangible book value per share0.0372
More ▼

Balance sheet in AUDView more

Argent Biopharma Ltd has a Debt to Total Capital ratio of 41.04%.
Current ratio0.7551
Quick ratio0.6561
Total debt/total equity0.3449
Total debt/total capital0.4104
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.